Patents by Inventor Ute Scholl

Ute Scholl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for diagnosing and treating diseases and disorders associated with mutant KCNJ5
    Patent number: 11484543
    Abstract: The present invention relates to the discovery that mutant KCNJ5 is associated with adrenal diseases and disorders. The invention includes compositions and methods for the diagnosis and treatment of adrenal diseases and disorders, based upon the presence or absence of a KCNJ5 mutation that is associated with an adrenal disease or disorder.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: November 1, 2022
    Assignee: The Rockefeller University
    Inventors: Richard Lifton, Ute Scholl
  • Loss of Function mutations in KCNJ10 cause SeSAME, a human syndrome with sensory, neurological, and renal deficits
    Publication number: 20200362008
    Abstract: The invention includes a method of identifying a human subject at-risk of developing SeSAME syndrome. The invention also includes a method of diagnosing a human subject afflicted with SeSAME syndrome. The invention further includes a method of identifying a therapeutic agent that modulates a given KCNJ10 mediated K+ current in a mammalian cell. The invention also includes a method of diagnosing a subject as a carrier of SeSAME syndrome.
    Type: Application
    Filed: May 27, 2020
    Publication date: November 19, 2020
    Inventors: Richard P. LIFTON, Ute SCHOLL
  • Loss of function mutations in KCNJ10 cause SeSAME, a human syndrome with sensory, neurological, and renal deficits
    Patent number: 10696729
    Abstract: The invention includes a method of identifying a human subject at-risk of developing SeSAME syndrome. The invention also includes a method of diagnosing a human subject afflicted with SeSAME syndrome. The invention further includes a method of identifying a therapeutic agent that modulates a given KCNJ10 mediated K+ current in a mammalian cell. The invention also includes a method of diagnosing a subject as a carrier of SeSAME syndrome.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: June 30, 2020
    Assignee: Yale University
    Inventors: Richard P. Lifton, Ute Scholl
  • COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING DISEASES AND DISORDERS ASSOCIATED WITH MUTANT KCNJ5
    Publication number: 20200147113
    Abstract: The present invention relates to the discovery that mutant KCNJ5 is associated with adrenal diseases and disorders. The invention includes compositions and methods for the diagnosis and treatment of adrenal diseases and disorders, based upon the presence or absence of a KCNJ5 mutation that is associated with an adrenal disease or disorder.
    Type: Application
    Filed: May 18, 2018
    Publication date: May 14, 2020
    Inventors: Richard Lifton, Ute Scholl
  • Loss of Function mutations in KCNJ10 cause SeSAME, a human syndrome with sensory, neurological, and renal deficits
    Publication number: 20170298114
    Abstract: The invention includes a method of identifying a human subject at-risk of developing SeSAME syndrome. The invention also includes a method of diagnosing a human subject afflicted with SeSAME syndrome. The invention further includes a method of identifying a therapeutic agent that modulates a given KCNJ10 mediated K+ current in a mammalian cell. The invention also includes a method of diagnosing a subject as a carrier of SeSAME syndrome.
    Type: Application
    Filed: April 28, 2017
    Publication date: October 19, 2017
    Inventors: Richard P. LIFTON, Ute SCHOLL
  • Loss of function mutations in KCNJ10 cause SeSAME, a human syndrome with sensory, neurological, and renal deficits
    Patent number: 9732138
    Abstract: The invention includes a method of identifying a human subject at-risk of developing SeSAME syndrome. The invention also includes a method of diagnosing a human subject afflicted with SeSAME syndrome. The invention further includes a method of identifying a therapeutic agent that modulates a given KCNJ10 mediated K+ current in a mammalian cell. The invention also includes a method of diagnosing a subject as a carrier of SeSAME syndrome.
    Type: Grant
    Filed: February 9, 2011
    Date of Patent: August 15, 2017
    Assignee: Yale University
    Inventors: Richard P. Lifton, Ute Scholl
  • Loss of Function mutations in KCNJ10 cause SeSAME, a human syndrome with sensory, neurological, and renal deficits
    Publication number: 20110195863
    Abstract: The invention includes a method of identifying a human subject at-risk of developing SeSAME syndrome. The invention also includes a method of diagnosing a human subject afflicted with SeSAME syndrome. The invention further includes a method of identifying a therapeutic agent that modulates a given KCNJ10 mediated K+ current in a mammalian cell. The invention also includes a method of diagnosing a subject as a carrier of SeSAME syndrome.
    Type: Application
    Filed: February 9, 2011
    Publication date: August 11, 2011
    Inventors: Richard P. Lifton, Ute Scholl